Search results for "Circulating tumor DNA"
showing 4 items of 34 documents
A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer
2019
El cáncer colorrectal (CCR) es un importante problema de salud pública. Más de 1.2 millones de pacientes se diagnostican de CCR cada año, y más de 600.000 mueren a causa de la enfermedad. El pronóstico de los pacientes con CCR ha mejorado durante las últimas décadas, con una supervivencia a los 5 años que ha alcanzado casi el 65% en países desarrollados. El estadio al diagnóstico es actualmente el factor pronóstico más importante. Aunque la clasificación clásica de estadiaje proporciona información pronóstica y guía las decisiones terapéuticas, no disponemos hoy en día de marcadores predictivos de la respuesta y del resultado clínico de la terapia individual del paciente. Esto es relevante …
Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood
2016
Opsoclonus–myoclonus syndrome (OMS) is a rare paraneoplastic, postinfectious, or parainfectious or idiopathic acute neurological syndrome in children and adults. OMS is characterized by involuntary...
Liquid Biopsy in Gastrointestinal Stromal Tumor
2017
Over the past 15 years, gastrointestinal stromal tumors (GISTs) have emerged from a poorly understood neoplasm to a well-defined tumor entity. Starting from 2000, the discovery of gain-of-function mutations involving KIT or PDGFRα (platelet-derived growth factor-α) genes and the development of tyrosine kinase inhibitors (TKIs), such as imatinib, revolutionized dramatically the management of GISTs. Due to the almost continual emergence of new data about biological complexity of GISTs and more sophisticated whole-genome technologies, to date, the role of molecular biology is clinically important to drive therapeutic decision making. The possibility of using liquid biopsy in GISTs was reported…
Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers
Background: Liquid biopsy is considered a repeatable, non-invasive and dynamic tool. It could be able to recover from liquid samples (expecially blood)) cancer-specific informations (miRNAs, circulating-free DNA (cfDNA), circulating tumor DNA (ctDNA) and exosomes) by overcoming the limitations associated with traditional tissue biopsy. Aim: to investigate the potential prognostic and predictive role of blood cancer-related biomarkers such as cfDNA or ctDNA and exosomal DNA in colorectal cancer (CRC) patients. Results: cfDNA or ctDNA and exosomal DNA could have a potential applicability in CRC management. New generation technologies are able to identify clinically relevant genomic alteration…